Joint ACS/AACR meeting on biological chemistry of inflammation in cancer
A meeting notice arrived in my e-mail yesterday that is particularly timely during my first month as a CENtral Science blogger. The Chemistry in Cancer Research (CICR) working group of my primary scientific society, the American Association for Cancer Research (AACR), will be hosting a joint meeting with ACS in San Diego in early 2011:
A joint meeting between the AACR and the American Chemical Society
Chemistry in Cancer Research: The Biological Chemistry of Inflammation as a Cause of Cancer
January 30 - February 2, 2011
Grand Hyatt Manchester Hotel
San Diego, CA
Peter C. Dedon, M.D., Ph.D., Massachusetts Institute of Technology, Cambridge, MA
Early registration deadline: Monday, November 1
Abstract submission and award application deadline: Wednesday, December 1
Chemistry plays a critical role in research on cancer diagnosis, prevention, and treatment. The AACR created the Chemistry in Cancer Research Working Group (CICR) to increase the profile of chemists within the Association and to strengthen their role in setting its research agenda.
You are invited to submit an abstract and register for this important conference, which is the third joint meeting between CICR and the American Chemical Society. As with the previous two joint conferences, it will continue to address the role of chemistry in cancer research with a specific focus on inflammation. Short presentations from abstracts submitted by early-career investigators are a key part of the program, as they energize and inform younger investigators of the many applications of chemistry to problems in cancer research. Also, the conference will feature a professional advancement session.
Session topics include:
• infection, inflammation, and cancer;
• chemical mediators of inflammation;
• biomarkers of inflammation; and,
• chemoprevention and drug development.
For more information, view the program. We hope to see you in San Diego early next year.
I really like the emphasis on early-career investigators and the overall promotion of chemistry among cancer researchers. Not to generalize (but I will), industrial cancer researchers seem to have an immense respect for their chemistry colleagues but many of my academic colleagues seem not have the same attitude.
The fact that AACR and ACS have entered this partnership is a good example for all and I hope that academic cancer researchers especially take advantage of this unique opportunity.
I know that it will be a great sacrifice to endure the January/February weather in San Diego but I encourage you to make an effort.